TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - SANOFI Share Price

Certificat

DE000SU0YT04

Market Closed - Deutsche Boerse AG 20:46:39 28/06/2024 BST
7.87 EUR -0.51% Intraday chart for TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - SANOFI
Current month-0.51%
1 month-2.84%
Date Price Change
28/06/24 7.87 -0.51%
27/06/24 7.91 +0.89%
26/06/24 7.84 +2.75%
25/06/24 7.63 -2.18%
24/06/24 7.8 -3.47%

Delayed Quote Deutsche Boerse AG

Last update June 28, 2024 at 08:46 pm

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying SANOFI
IssuerLogo Issuer Société Générale Société Générale
WKN SU0YT0
ISINDE000SU0YT04
Date issued 20/10/2023
Strike 168.7
Maturity Unlimited
Parity 10 : 1
Emission price 7.53
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 9.27
Lowest since issue 7.24

Company Profile

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Sector
-
More about the company

Ratings for Sanofi

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Sanofi

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
89.94 EUR
Average target price
107.9 EUR
Spread / Average Target
+19.93%
Consensus